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Executive Summary  
 
 Investigation of mechanisms governing development and normal and abnormal 
function of the human central nervous system (CNS) is hampered by its complexity 
and the very limited possibility of experimentally manipulating it in-vivo.  
 
 Development of 3-dimensional (3D), tissue-like culture systems offers much promise 
for boosting our understanding of human neural development, birth defects, 
neurodegenerative diseases and neural injury 
 
 3D models of the human CNS can provide platforms that will allow us to more 
accurately predict efficacy of putative therapeutic compounds and assess responses to 
potentially neurotoxic agents.  
 
 Novel technological developments and a more interdisciplinary approach to 
modelling the human CNS underpin development of these model  
 
 As we increase the complexity of in-vitro systems to make them more tissue-like, the 
challenge of establishing highly reproducible models amenable to quantitative and 
high throughput analysis also increases.   
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Abstract 
 
Studying the cellular and molecular basis governing development and normal and abnormal 
function of the human central nervous system (hCNS) is hampered by its complexity and the 
very limited possibility of experimentally manipulating it in-vivo. Development of 3-
dimensional, tissue-like culture systems offers much promise for boosting our understanding 
of human neural development, birth defects, neurodegenerative diseases and neural injury, and 
for providing platforms that will more accurately predict efficacy of putative therapeutic 
compounds and assess responses to potentially neurotoxic agents. While novel technological 
developments and a more interdisciplinary approach to modelling the hCNS are accelerating 
the pace of discovery, increasing the complexity of in-vitro systems increases the ordeals to be 
overcome to establish highly reproducible models amenable to quantitative analysis.   
 
Keywords: central nervous system, development, disease, human, in vitro modelling, stem 
cells 
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Article 
The central nervous system (CNS), including brain and spinal cord, is the most complex tissue 
in the body, both structurally and functionally. The main CNS components are the neurons and 
their extensions, glial cells (oligodendrocytes and astrocytes), vascular cells, immune cells and 
other support cells. The human brain contains approximately 100 billion neurons and a typical 
neuron has about 5000-200,000 synapses [1]. Finely tuned interactions between all different 
cell types through both physical and biochemical mechanisms lead to a highly sensitive and 
well-regulated environment [2]. The complexity of the human brain together with the limited 
possibility of experimentally manipulating it in vivo, however, poses major challenges to study 
mechanisms governing human neural development, neurodegenerative diseases and responses 
to injury at the cellular and molecular level. The results of animal studies, though of crucial 
importance to provide insights in some of these mechanisms, cannot be simply extrapolated to 
humans. Rodents have reduced cognition, less complex brain structure and transgenic animal 
models of neural diseases often lack features of the pathological phenotype observed in 
humans; examples of human neurological diseases that are challenging to model in animals 
include amyotrophic lateral sclerosis (ALS), Huntington disease and Parkinson disease and 
autism [3-8]. Furthermore, some of the species that might better recapitulate certain human 
neurological diseases are not traditional laboratory animals; hence, in addition to ethical issues 
and the high cost involved working with these models, there is a lack of suitable reagents 
available for their effective in depth study [4, 5, 9]. There are some significant differences 
between humans and rodents also at the cellular and molecular level; for example, rodent cells 
have longer telomeres that can account for differences in the severity of disease phenotype as 
compared to humans, and can respond differently to growth factors, cytokines and several toxic 
agents [10-15].  
Hence it is not all that surprising that many CNS-targeted therapeutics that offer much promise 
in animal models of neural diseases fail in clinical trials. A key challenge is to develop tools to 
bridge this gap in order to improve our understanding of healthy and diseased human CNS at 
the cellular and molecular levels, and better predict efficacy of novel therapeutic strategies in 
humans. [16]. Because of the obvious ethical constraints, this has to be achieved by modelling 
the human CNS in vitro.  
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 “Old” and” new” cell sources for human neural tissue modelling 
In vitro models, that have largely been 2-dimensional (2D, monolayers), significantly reduce 
the complexity of the whole organism into a more defined and controlled system, allow easy 
manipulation of both cells and their environment and thus allow us to study phenomena that 
cannot be observed or measured in vivo.  
Because of the limited availability of human tissue and the need for large quantities of material, 
especially for biochemical and pharmacological studies, human neural cell lines have been 
much used in neuroscience. Many commonly used human cell lines were derived from 
naturally occurring tumours such as astrocytomas (e.g.U-87, U-251), oligodendrogliomas (e.g. 
HOG), ependymomas, glioblastomas, and primitive neuroectodermal tumors (e.g. TERA-2 and 
its subclone, the NT-2 line) [17]. Neuroblastomas, child solid tumours composed of neural 
crest derived precursors of the sympathetic nervous system, have been also extensively used 
as an easily available source of neuronal-like cells (e.g. SH-SY5Y) as following differentiation 
they display many feature of dopaminergic neurons [18]. In general, transformed human neural 
lines maintain some of the properties of native cells; therefore, as long as these models’ 
limitations are taken into account, they can provide useful tools particularly for cellular and 
molecular studies (e.g. investigation of signalling pathways). 
The use of non-tumor-derived human neural cells has significantly gained momentum over the 
last couple of decades following the discovery of neural stem cell presence not only in the 
developing CNS but also postnatally, and the development of strategies for their isolation, 
long-term culture and differentiation into neurones and glia (astrocytes and oligodendrocytes). 
This has gone hand in hand with developing protocols to generate different neural cell types 
from pluripotent human embryonic stem cells (ESCs). ESCs have self-renewal ability and 
readily proliferate, thus allowing generation of neuronal and glial cells in relatively large 
numbers [16, 19]. However, apart from the ethical issues concerning the use of ESC, these cells 
are usually derived from supposedly normal embryos. While they can be very valuable for 
assessing toxicity to different neural and glial populations [20], they are not directly suitable 
for disease modelling unless modified to carry mutations of interest when the disease cause is 
known. In the last few years, modelling of human neural diseases has been galvanized by the 
development of reprogramming techniques that allow generation of induced pluripotent stem 
cells (iPSCs) from patients’ somatic cells (e.g. skin fibroblasts, blood cells) which can be also 
valuable for autologous stem cell therapy [21, 22]. iPSCs have ESC-like properties and their 
use circumvents ethical issues. Their downside is that reprogramming is a lengthy and costly 
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process and that cell from patients are not always readily available to researchers. Several iPSC 
lines from patients with a number of neural diseases (e.g. spinal muscular atrophy, amyotrophic 
lateral sclerosis, Alzheimer’s disease, ataxia telangiectasia, Down syndrome, familial 
dysautonomia, fragile X syndrome, Friedrich ataxia, Huntington’s disease, Niemann-Pick 
disease, Parkinson’s disease, schizophrenia) have already been generated and their number is 
continuously increasing [23]. Significantly, the number of open-access repositories of cells 
from patients carrying a variety of diseases is also rapidly increasing, with some focusing on 
neural diseases, but more are needed [24, 25].  It will be crucial to ensure long-term funding 
for maintenance and expansion of these important resources and guarantee their availability to 
the wider scientific community.  
An example of how an iPSC-based model can be relevant to studying a disease and for 
therapeutic development is that of amyotrophic lateral sclerosis (ALS). This fatal disease is 
caused by mutations in superoxide dismutase 1 (SOD1) that lead to spinal neurone loss with 
consequent muscle wasting and paralysis. Currently, the only drug available to ALS patients 
merely delays the onset of some disease traits. The discovery of new drugs for ALS has been 
hampered by the lack of suitable models for preclinical testing as rodent models do not entirely 
mimic the human disease phenotype [3, 5]. Neurones from ALS patient-derived iPSCs were 
found to display disease characteristics and have provided valuable insights into the activity of 
different drugs [25]. 
Moving towards neural tissue-like structures 
Together, iPSCs provide a unique tool for studying human neural diseases for which there are 
no transgenic animal models fully reproducing the disease phenotype [16]. However, they have 
so far been mainly used in 2D cultures. While such cultures allow easy expansion, monitoring, 
and manipulation of cells, they also impose highly unnatural constraints on the cells. Cell 
behaviour, morphology and gene expression under these conditions can differ significantly 
from those observed in vivo. In addition, cells grown as monolayers often appear to be more 
susceptible to drugs and therapeutic agents ([26-28] and our paper in preparation). With 
increasing awareness of the importance of the environmental context for cell physiology, 
interest is growing in developing more complex cell culture systems that better reflect the 
situation in vivo and thus allow the cells to behave in a physiologically more relevant manner. 
To achieve this goal key properties of tissues need to be reproduced as closely as possible in 
the in vitro models  (Figure 1).  
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Development of three-dimensional (3D) human culture models can bridge the gap between 
native tissue and monolayer cell culture systems and increase the relevance of in vitro studies. 
A 3D architecture reduces the strain and artificial responses cells undergo to adapt to a flat 
surface as it allows them to spread and interact with adjacent cells in all dimensions. This 
results in different modulation of microenvironmental cues such as cell-cell and cell-matrix 
interactions, mechanical forces and diffusible factors providing a more natural environment 
that supports formation of a tissue-like architecture and can allow tackling questions that 
cannot be addressed in 2D systems [29, 30]. For example, modelling human CNS traumatic 
injuries using compressive impacts could not be achieved in 2D cultures [31].  
The idea that 3D is better than 2D is not new. The oldest complex 3D systems used in 
neuroscience are organotypic cultures (derived from small explants or slices) where the 
cytoarchitecture of the tissue is largely maintained. Thin slices of brain or spinal cord can be 
kept alive for extended periods of time allowing cell labelling, manipulations, and live cell 
monitoring, including electrophysiological measurements. However, they are technically 
demanding, can be very variable and, in the case of human neural tissue, there is obviously 
limited tissue availability. Nonetheless, in a few studies, neural tissue from human foetal brain 
or spinal cord culture was used to study human CNS development [17, 32, 33] and more 
recently post-mortem human brain slices were shown to be suitable for optogenetic studies 
[34]. 
Nevertheless, as discussed above, if we are to model neural diseases, either patient-derived 
iPSCs, or ESCs or neural stem cells modified to carry the defective disease causing gene need 
to be used, and conditions that will give rise to a neural-like tissue in culture established.  
The 3D model of choice, the complexity one aims to achieve and the strategy to be used to 
build it will depend on the specific questions to be addressed using that model. For example, 
when models are needed for studying mechanisms of human CNS development and disease, it 
can be acceptable to use systems that will slowly become organised into neural-like tissues and 
use quite complex and relatively time-consuming analytical approaches.  In contrast, if a 
system is to be used for initial drug screening, it needs to be relatively easy to handle, 
inexpensive, highly reproducible, and able to provide clear readouts with medium to high 
throughput.  
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Although the notion of bottom-up and top-down approaches is more commonly used in the 
context of tissue engineering, these approaches, either alone or in combination, can also be 
broadly applied to the construction of neural models [16]. 
In the bottom-up approach a model is put together from individual components to give rise to 
a more complex system. With this approach, cellular (e.g., phenotypes, ratios, densities) 
scaffold parameters (controlling mechanical properties and bioactive motifs) and construction 
approach (e.g. bioprinting) are defined to design and build the model in as controlled fashion 
as possible. They usually involve the use of a scaffold, and the type of scaffold selected depends 
on the desired characteristics and functionality of the 3D culture and on the method chosen to 
“build the tissue”. For example, a relatively simple 3D model involves the use of rigid 
polystyrene scaffolds where human NSCs can be grown and induced to differentiate into 
mature neurons that form active and functional neuronal networks [35]. Hydrogels rich in brain 
extracellular matrix proteins, such as Matrigel, are extensively used to “glue” cells together in 
a 3D environment; as these scaffolds are not rigid, they allow for remodelling and are used also 
for top-down modelling. To give an example, Matrigel-embedded human NSCs over-
expressing mutated human β-amyloid precursor protein and presenilin 1 have been used to 
establish a model of Alzheimer’s disease. Upon induction of neuronal differentiation, these 
cells successfully recapitulated amyloid-β and tau pathology with robust extracellular 
deposition of amyloid-β plaques [36].  This model of Alzheimer’s disease, as well models of 
other human neurodegenerative disorders developed using a similar strategy, will be valuable 
both for better understanding disease mechanisms and for therapeutics development.  
The bottom-up approach could also allow generation of neural tissue of greater complexity by 
modular and patterned inclusion in the selected scaffold of different cell types (e.g. neurones, 
astrocytes, oligodendrocytes, microglia and endothelial cells) to interrogate their roles and 
interactions in biological processes. For example, it is difficult to study myelination and 
interactions between oligodendrocytes, the myelin-forming cells in the CNS, and neurons in 
the human developing brain, as it is currently hard to achieve efficient differentiation of hNSCs 
into oligodendrocytes and significant myelination in vitro. This is a bit of a vicious circle and 
highlights the inadequacy of the models used, as much information on the mechanisms 
regulating this process in the human brain is still missing, and myelination is a very “spatial” 
process that requires a 3D system. It is becoming apparent from animal studies that the 
developmental age of the oligodendrocytes and the presence of astrocytes may be key to 
efficient myelination [37]. This could be tested by systematically building human 3D models 
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of different cellular composition. Availability of robust 3D human myelination models is 
crucial if we are to better understand its development, homeostasis and the process of 
demyelination-remyelination in neurodegenerative diseases such as multiple sclerosis (MS), as 
well as in response to injury.  
One of the newest technologies applied in the bottom-up approach is 3D bioprinting, where 
complex 3D structures are fabricated through layer-by-layer precise positioning of biological 
materials, biochemicals and living cells, with very accurate spatial control of the placement of 
functional components. Bioprinting also allows high-throughput generation of replicas of 
spatially and temporally well-controlled complex constructs [38, 39]. The first example of 
fabricating human neural tissue by 3D bioprinting neural stem cells has been recently reported 
[40]; this opens new avenues to the development of more finely controlled and reproducible 
neural in vitro models.   
The top-down approach to 3D modelling largely relies on the intrinsic ability of the cells to 
form complex structures, called organoids, usually within soft matrices [41, 42]. Cortex-like 
structures have been generated by allowing either a mixture of cells derived from human fetal 
brain or ESCs to self-organize in 3D usually within a hydrogel [42-44]. Well-controlled 3D 
aggregates of human ESCs spontaneously differentiated into cortical progenitors and 
functional neurons forming concentric patterned structures that mimicked early stages of 
corticogenesis and expressed markers of different cortical layers [42, 45-48] and references 
within). The self organising ability of human ESCs has indeed been demonstrated in several 
subsequent studies showing formation of cortex-like neuroepithelial cell layers, entire optic 
cups (primitive eye structures) [49], and stratified retinas [42, 46-48, 50]. A limiting factor for 
successful long-term maintenance and maturation of organoids is nutrient availability. By using 
a spinning bioreactor to enhance nutrient absorption, ESCs in Matrigel droplets can be 
maintained in culture for months (up to 10 months), allowing formation of brain organoids 
containing discrete regions that resemble cerebral cortex, ventral telencephalon, choroid plexus, 
retina and meninges [45]. The same approach was used to generate brain organoids from 
microcephaly patient-specific iPSCs to model this neurodevelopmental disorder in vitro [45]. 
The use of iPSC-derived neural organoids is rapidly expanding, and they have been recently 
used to study autism spectrum disorder, to model the effect of Zika virus infection, and to 
investigate evolutionary mechanisms underlying expansion of the human cortex, just to give 
some examples [46-48].  
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Challenges ahead 
Notwithstanding all these exciting developments, establishment of highly reproducible 3D 
neural models is still in its infancy and presents several challenges (Figure 2). First of all the 
brain tissue has very high cellularity with little ECM. The average cell density in the brain is 
thought to exceed 100,000 cells/μL. Cell density has been shown to influence cell behaviour, 
including survival and differentiation [2]. Most culture systems cannot accurately reproduce 
this high cell density that is usually an order of magnitude lower than that found in vivo [51]. 
As already mentioned, high cellular densities raise the issue of adequate nutrient supply. 
Passive diffusion of nutrients and gasses is not sufficient to meet the metabolic demands of 
these dense cultures and further development of bioreactors providing continuous medium 
perfusion will be necessary [52]. Another approach to address these difficulties is 
miniaturization of the whole system using microfluidic devices [46]. Miniaturized culture 
chambers can provide high-resolution spatiotemporal control of the extracellular environment 
and reduce the number of cells and expensive reagents required. A number of models 
mimicking hypoxic neural stem niche, neuron-glia interactions, neurovascular unit and blood 
brain barrier, and culture of cells under dynamic interstitial fluid flow conditions have already 
been developed [20, 53-57]. In combination with 3D cultures “brain on chip” platforms offer 
a great system for studying physiology, injury or development at a single cell resolution as well 
as cytotoxicity or drug screenings. 
Another big challenge in working with 3D culture models, that currently hinders their ease of 
use, is the lack of simple and reliable assays for detailed analysis and interpretation of cellular 
responses. Evaluation of basic parameters such as cell number, viability, morphology and 
functional testing is much more complicated in a 3D cell culture setting, particularly as its size 
increases, as compared to a 2D system. Development of robust, yet reasonably simple, methods 
for live cell imaging and functional evaluation of 3D in vitro models, including analysis of 
metabolic activities and electrophysiological responses, will be crucial. Without a thorough 
assessment of their properties, 3D models cannot be validated as true in vitro “neural tissue 
surrogates”. Further development of micro-electrode array (MEA) technology could offer a 
solution to this problem and underpin development of the next-generation of 3D neural culture 
models. [16, 35, 58]. 
Together, future development of reproducible and cost-effective human 3D models suitable for 
assessing mechanisms of neural development and disease, efficacy of therapeutic agents, or 
toxic responses, will require an extensive and well-integrated multidisciplinary effort [59, 60]. 
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Although further refinement of 3D neural culture systems is much needed, it is already apparent 
that this in vitro approach can provide more tissue-like and physiologically relevant models for 
the study of the healthy and diseased human CNS, and help to increase accuracy in the 
evaluation of potential therapeutics, while reducing the need for animal studies. 
Finally, the availability of physiologically relevant 3D neural culture models, together with a 
better understanding of neural disease mechanisms and identification of novel neural tissue-
compatible scaffolds, might aid development of a diverse range of therapeutic approaches. For 
example, it could provide valuable references for the development and testing of novel matrices 
that can fill brain cavities following traumatic injury or stroke and be cellularised by 
endogenous cells [61-64], or aid devising cell-based systems for the delivery of neuroprotective 
factors in diseased brains [65].     
Future Perspective   
Development of human neural disease 3D models is taking momentum. It is anticipated that 
over the next few years interdisciplinary effort between biologists, physiologists, engineers and 
material scientists will accelerate establishment of reproducible human CNS models in vitro 
and will support more automated analysis of cellular, molecular and physiological responses. 
 Such effort will provide a range of novel platforms that will be valuable both for understanding 
human disease mechanisms and for performing initial medium/high throughput screenings of 
neuroactive compounds with increased power for predicting therapeutic potential, as well as 
neurotoxic effects, in humans. The advantages of this approach will not only be a significant 
reduction in the use of animals at the early stages of the drug discovery process, or in 
developmental neurotoxicology studies, but also a more in depth knowledge of the human 
disease mechanisms and a better understanding of interspecies differences. This in turn will 
help to develop/select better animal models for subsequent in vivo studies that are mandatory 
prior to clinical trials, that will underpin a more accurate interpretation of the results, hence 
reducing the risk of failure at advanced stages of therapeutic development.  
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Figure Legends 
 
Figure 1. Microenvironmental factors affecting cell behaviour. In vivo there are several 
factors that change temporally and spatially and substantially affect cellular behaviour within 
a tissue; some key ones are indicated. These factors need to be taken into account when 
designing 3-dimensional culture model with the aim of reproducing as accurately as possible a 
physiological cell behaviour within a tissues. 
 
 
Figure 2. Summary of key steps and bottlenecks for the development of 3D in vitro models 
of human neural tissue. The central image shows a 3D culture of human embryonic neural 
stem cells neuronally differentiated in Matrigel and stained for ß3-tubulin (green), GFAP (red) 
and nuclei (blue). 
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Figure 1. Microenvironmental factors affecting cell behaviour. In vivo there are several 
factors that change temporally and spatially and substantially affect cellular behaviour within a 
tissue; some key ones are indicated. These factors need to be taken into account when 
designing 3-dimensional culture model with the aim of reproducing as accurately as possible a 
physiological cell behaviour within a tissues. 
• Cell-cell communication 
(polarity, signaling) 
THREE-DIMENSIONALITY IN VITRO 
• Matrix properties 
 chemical composition, 
 physical properties (rigidity)  
• Vascularisation 
(oxygen, nutrients, trophic factors) 
• Nutrients, 
oxygen availability 
• Mechanical stress, 
 fluid flow 
TISSUE – IN VIVO 
 19 
 
 
 
 
 
1. Cells:  
source, type(s), density, 
differentiation protocols 
3. Environmental control: 
large scale, miniaturization 
4. Tools for functional analysis: 
imaging, biochemistry, electrophysiology 
2. 3D environment: 
scaffold with defined structure, 
possibility of self-assembly  
 
Figure 2. Summary of key steps and bottlenecks for the development of 3D in vitro 
models of human neural tissue. The central image shows a 3D culture of human 
embryonic neural stem cells neuronally differentiated in Matrigel and stained for ß3-tubulin 
(green), GFAP (red) and nuclei (blue). 
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